{"product_id":"prva-vrio-analysis","title":"Privia Health Group, Inc. (PRVA): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Privia Health Group, Inc. (PRVA)'s enduring success by examining its core capabilities through the VRIO framework. This analysis cuts straight to the chase, revealing whether its current assets are truly Valuable, Rare, Inimitable, and Organized enough to secure a sustainable competitive advantage. Don't just guess its market strength - read the distilled findings below to see exactly where Privia Health Group, Inc. (PRVA) stands.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrivia Health Group, Inc. (PRVA) - VRIO Analysis: 1. Technology-Enabled Physician Enablement Platform\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core engine of Privia Health Group, Inc. (PRVA), and frankly, it’s where the value is truly built. This platform isn't just software; it's the operational backbone that lets their network of physicians actually thrive in value-based care (VBC).\u003c\/p\u003e\n\n\u003ch3\u003eValue: Core Infrastructure for VBC Success\u003c\/h3\u003e\n\u003cp\u003eThe platform delivers the essential infrastructure - the software, the databases, and the hard-earned know-how - that cuts down on the paperwork doctors hate and gives them data to make better patient decisions. This directly supports their mission to empower physicians to succeed under VBC models. For instance, in Q3 2025, this execution helped drive practice collections up by \u003cstrong\u003e27.1%\u003c\/strong\u003e year-over-year to \u003cstrong\u003e$940.4 million\u003c\/strong\u003e. It’s the mechanism that turns clinical quality into financial reward.\u003c\/p\u003e\n\u003cp\u003eThe platform’s impact is clear when you look at the Medicare Shared Savings Program (MSSP) results for the 2024 performance year, which were discussed in the Q3 2025 call. Privia’s networks generated over \u003cstrong\u003e$234 million\u003c\/strong\u003e in total shared savings, with the gross share to doctors and the company exceeding \u003cstrong\u003e$160 million\u003c\/strong\u003e. That’s real money flowing because the tech works.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Deep Multi-Payer VBC Integration\u003c\/h3\u003e\n\u003cp\u003eSure, lots of companies offer tech tools, but Privia’s platform is different because it’s deeply woven into Electronic Medical Records (EMRs) and specifically engineered for the complexities of multi-payer, value-based care workflows. Most tools are just for billing or simple telehealth, which is far more common. Privia’s network, as of Q3 2025, included \u003cstrong\u003e5,250\u003c\/strong\u003e implemented providers across 15 states and D.C., all using this specialized system. That scale and specific integration are not easily found.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on scale versus the market: while they grew implemented providers by \u003cstrong\u003e13.1%\u003c\/strong\u003e year-over-year in Q3 2025, their ability to handle shared-risk arrangements across multiple payers sets them apart from pure-play revenue cycle management (RCM) vendors.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Years of Confidential Know-How\u003c\/h3\u003e\n\u003cp\u003eReplicating this platform is tough and slow. It’s not just about coding; it’s built on years of proprietary technology development and confidential operational knowledge gained from managing these complex VBC contracts. Copying the code is one thing; copying the institutional knowledge that makes the code effective in the real world is another. The company’s operating margin expansion, up from 1.3% to 2.5% year-over-year in Q3 2025, shows this know-how is translating to efficiency. It’s a high barrier to entry.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Commitment to Exploitation\u003c\/h3\u003e\n\u003cp\u003eThe organization is definitely committed to using this asset, not just sitting on it. They consistently invest in rolling out platform upgrades, like the AI assistant mentioned in their strategy discussions. This shows a strong organizational structure geared toward exploiting the technology for better results. For example, their Q3 2025 Adjusted EBITDA hit \u003cstrong\u003e$38.2 million\u003c\/strong\u003e, a \u003cstrong\u003e61.6%\u003c\/strong\u003e increase year-over-year, demonstrating they are organized to convert platform capabilities into profit.\u003c\/p\u003e\n\u003cp\u003eWhat this estimate hides is the integration risk of their recent strategic move - the acquisition of Evolent Health’s ACO business, which adds over 120,000 attributed lives. If onboarding takes 14+ days longer than planned, integration churn risk rises.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage Scoring\u003c\/h3\u003e\n\u003cp\u003eThe platform is the central nervous system connecting all their other capabilities, which is why it earns a top score. It’s not just a resource; it’s the foundation.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eScore\u003c\/td\u003e\n\u003ctd\u003eCompetitive Implication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eReduces burden, enables VBC revenue capture\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eCompetitive Parity to Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eDeep, multi-payer VBC workflow integration\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eBuilt on years of proprietary tech and know-how\u003c\/td\u003e\n\u003ctd\u003eDifficult\/Costly\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eConsistent investment, strong operational leverage\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eSustained Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe platform is the key to their growth story, which management expects to continue, raising full-year 2025 revenue guidance to a midpoint of \u003cstrong\u003e$2.08 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe key takeaways for your action plan are:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMonitor integration of the Evolent ACO business.\u003c\/li\u003e\n\u003cli\u003eTrack provider adoption rates on the platform.\u003c\/li\u003e\n\u003cli\u003eBenchmark platform-enabled MSSP savings in 2025.\u003c\/li\u003e\n\u003cli\u003eAssess R\u0026amp;D spend on platform enhancements.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrivia Health Group, Inc. (PRVA) - VRIO Analysis: 2. Value-Based Care (VBC) Performance \u0026amp; Shared Savings Generation\n\u003c\/h2\u003e\n\n\u003cp\u003eValue: It directly translates into cash flow via shared savings from payers, proving the model works.\u003c\/p\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eIn the 2024 performance year of the Medicare Shared Savings Program (MSSP), Privia Health Group achieved shared savings of \u003cstrong\u003e$233.1 million\u003c\/strong\u003e, representing a \u003cstrong\u003e32%\u003c\/strong\u003e year-over-year increase from 2023.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eCompetitors face challenges in consistently achieving high savings rates against benchmarks.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e2024 MSSP Aggregate Savings Rate: \u003cstrong\u003e9.3%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMid-Atlantic ACO 2024 Savings Rate: \u003cstrong\u003e10.9%\u003c\/strong\u003e, the highest among all MSSP ACOs with more than \u003cstrong\u003e40,000\u003c\/strong\u003e attributed lives.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eReplicating the clinical performance that drives the savings takes time and network maturity.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric (2024 MSSP vs. FFS Medicare)\u003c\/td\u003e\n\u003ctd\u003eLower By\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeneficiary Expenditures\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e22%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInpatient Facility Spend\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e28%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutpatient Facility Spend\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e35%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eManagement consistently highlights VBC performance as a core driver, showing clear focus on maximizing attribution and savings.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal PQN Shared Savings since 2014 across all programs: Over \u003cstrong\u003e$1.5 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal PQN Shared Savings since 2014 through MSSP participation: \u003cstrong\u003e$922 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e2024 Aggregate Quality Score: \u003cstrong\u003e89%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eWhile strong now, sustained regulatory changes or payer contract shifts could erode this advantage if not continuously improved.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003ePerformance Year\u003c\/td\u003e\n\u003ctd\u003eACOs\u003c\/td\u003e\n\u003ctd\u003eTotal MSSP Shared Savings\u003c\/td\u003e\n\u003ctd\u003eAggregate Savings Rate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$233.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$176.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$131.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrivia Health Group, Inc. (PRVA) - VRIO Analysis: 3. Physician Autonomy and Partnership Model\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This cultural asset is crucial for attracting and retaining high-quality, independent physician groups who value clinical decision-making freedom over employment.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. In a market where many groups face pressure from private equity or health systems, Privia's physician-led governance and focus on autonomy is a rare selling point.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Culture and trust built over years with physician leaders are nearly impossible to copy quickly.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The model is central to their entire go-to-market strategy, evidenced by their ability to sign large, multispecialty groups despite competition.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This is a deep, organizational commitment that underpins provider network growth.\u003c\/p\u003e\n\n\u003cp\u003eThe success of the physician-centric model is quantified by network expansion and financial alignment:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023 Value\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003cth\u003eGrowth\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eImplemented Providers (Year-End)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4,305\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4,789\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e+11.2%\u003c\/strong\u003e Year-over-Year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMSSP Shared Savings (Performance Year)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$176.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$233.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e+32%\u003c\/strong\u003e from 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYear-End Cash Balance\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$390 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$491.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eNo Debt\u003c\/strong\u003e as of year-end 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eKey operational metrics demonstrating network engagement and scale:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGross provider retention maintained over \u003cstrong\u003e98%\u003c\/strong\u003e in 2023.\u003c\/li\u003e\n\u003cli\u003eTotal shared savings across all programs since 2014 exceeded \u003cstrong\u003e$1.5 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe nine ACOs managed over \u003cstrong\u003e$2.5 billion\u003c\/strong\u003e in healthcare benchmark spend in the 2024 performance year.\u003c\/li\u003e\n\u003cli\u003eThe company projects reaching \u003cstrong\u003e5,200 to 5,300\u003c\/strong\u003e implemented providers in 2025.\u003c\/li\u003e\n\u003cli\u003eTotal revenue for the full year 2024 was \u003cstrong\u003e$1.736 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrivia Health Group, Inc. (PRVA) - VRIO Analysis: 4. Diversified Payer\/Risk Contract Portfolio\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e It buffers the company against volatility in any single payment stream, like the Medicare Advantage (MA) headwinds seen industry-wide.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While diversification exists, Privia’s prudent mix - with data from Q2 2025 showing a significant commercial base and growth across government programs - shows strategic balance.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Building a balanced book across government and commercial payers takes time and market-by-market negotiation.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Management actively discusses its conservative stance on full-risk capitation, showing they are organized to manage risk exposure actively.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The current mix is advantageous, but payer dynamics are always shifting, requiring constant organizational adaptation.\u003c\/p\u003e\n\n\u003cp\u003eThe diversification is evidenced by the following real-life figures:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue \/ Growth Rate\u003c\/th\u003e\n\u003cth\u003ePeriod \/ Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Attributed Lives\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.38 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial Attributed Lives\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e843,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial Attributed Lives Percentage (Calculated)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~61.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCalculated from Q2 2025 data (843k \/ 1.38M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMS Medicare Programs Lives Growth\u003c\/td\u003e\n\u003ctd\u003eUp almost \u003cstrong\u003e15%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eYear-over-year as of Q2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare Advantage Attribution Growth\u003c\/td\u003e\n\u003ctd\u003eUp more than \u003cstrong\u003e13%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eYear-over-year as of Q2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicaid Attribution Growth\u003c\/td\u003e\n\u003ctd\u003eUp more than \u003cstrong\u003e31%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eYear-over-year as of Q2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal MSSP 2024 Shared Savings\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$234.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024 Performance Year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Total Attributed Lives (Post-Acquisition)\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e1.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePro forma with Evolent ACO acquisition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eKey financial performance metrics from the most recent reported quarter support the operational strength derived from this portfolio:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2025 Total Revenue: \u003cstrong\u003e$580.4 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Adjusted EBITDA: \u003cstrong\u003e$38.2 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Adjusted EBITDA Growth (vs 3Q'24): \u003cstrong\u003e+61.6%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrivia Health Group, Inc. (PRVA) - VRIO Analysis: 5. Geographic Density and Scale\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Scale drives operating leverage and provides a larger base for VBC savings capture. As of Q3 2025, they operate in \u003cstrong\u003e15 states\u003c\/strong\u003e with \u003cstrong\u003e5,250\u003c\/strong\u003e implemented providers.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Other players have scale, but Privia's density within specific markets, which management focuses on, is key to efficiency.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can enter new states, but achieving the same provider density in existing markets is slow and capital-intensive.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The 2025 plan explicitly targets increasing density in existing markets as a core execution pillar.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Network effects and established local relationships create a barrier to entry for new entrants.\u003c\/p\u003e\n\u003cp\u003eKey operational and financial metrics supporting scale and density:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$580.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePractice Collections\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$940.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$38.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImplemented Providers (Guidance)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5,325\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFY 2025 Year-End Target\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Attributed Lives (Approximate)\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e5.2 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eGrowth and Expansion Data:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eImplemented Providers increased by \u003cstrong\u003e13.1%\u003c\/strong\u003e versus 3Q'24.\u003c\/li\u003e\n\u003cli\u003ePractice Collections grew by \u003cstrong\u003e27.1%\u003c\/strong\u003e year-over-year in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eAdjusted EBITDA surged by \u003cstrong\u003e61.6%\u003c\/strong\u003e year-over-year in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eThe acquisition of Evolent Health's ACO business adds over \u003cstrong\u003e120,000\u003c\/strong\u003e attributed lives.\u003c\/li\u003e\n\u003cli\u003eFY'25 Guidance raised, projecting a \u003cstrong\u003e11.2%\u003c\/strong\u003e year-over-year increase in implemented providers by year-end.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrivia Health Group, Inc. (PRVA) - VRIO Analysis: 6. Operational Leverage in Mature Markets\n\u003c\/h2\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThis is pure profit acceleration; it means profits grow much faster than revenue. In mature markets, they expect \u003cstrong\u003e19%\u003c\/strong\u003e adjusted EBITDA growth from this leverage alone.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nModerate. It’s the result of successful scaling, not a starting asset, but Privia's mature markets are demonstrating it clearly.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nLow. It’s a lagging indicator of successful past execution (provider onboarding and platform integration).\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nHigh. The Q3 2025 results showed \u003cstrong\u003e61.6%\u003c\/strong\u003e Adjusted EBITDA growth, proving the organization can effectively convert revenue growth into disproportionate profit growth.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Actual\u003c\/th\u003e\n\u003cth\u003eYear-over-Year Change\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$38.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+61.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePractice Collections\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$940.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+27.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Margin (% of Care Margin)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e30.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+720 basis points\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImplemented Providers\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5,250\u003c\/strong\u003e (End of Q3)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e+13.1%\u003c\/strong\u003e vs 3Q'24\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nThe organization is positioned to convert future growth, with more than \u003cstrong\u003e80%\u003c\/strong\u003e of full-year 2025 Adjusted EBITDA expected to convert to free cash flow.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary. It relies on maintaining high utilization and controlling platform costs as the network matures.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nThe company's 2025 full-year Adjusted EBITDA growth guidance stands at \u003cstrong\u003e32%\u003c\/strong\u003e at the midpoint.\n\u003c\/li\u003e\n\u003cli\u003e\nTotal shared savings for the 2024 performance year reached \u003cstrong\u003e$234.1 million\u003c\/strong\u003e, a \u003cstrong\u003e32.6%\u003c\/strong\u003e increase from a year earlier.\n\u003c\/li\u003e\n\u003cli\u003e\nThe aggregate savings rate was \u003cstrong\u003e9.4%\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrivia Health Group, Inc. (PRVA) - VRIO Analysis: 7. Fortress Balance Sheet \u0026amp; Cash Position\n\u003c\/h2\u003e\n\u003cp\u003e\nValue: Provides immense flexibility for disciplined M\u0026amp;A, technology investment, and weathering industry downturns without needing external financing.\n\u003c\/p\u003e\n\u003cp\u003e\nRarity: High. Having zero debt and a strong cash position (near \u003cstrong\u003e$410 million\u003c\/strong\u003e pro forma after the Evolent deal) is rare in this capital-intensive sector.\n\u003c\/p\u003e\n\u003cp\u003e\nImitability: Low. Building this level of cash reserves and avoiding debt takes years of disciplined financial management.\n\u003c\/p\u003e\n\u003cp\u003e\nOrganization: High. Management consistently points to this 'fortress' balance sheet as a key enabler for strategic moves, like the Evolent acquisition.\n\u003c\/p\u003e\n\u003cp\u003e\nCompetitive Advantage: Sustained. Financial strength is a durable advantage that allows for opportunistic growth.\n\u003c\/p\u003e\n\u003ch3\u003eFinancial Metrics Snapshot\u003c\/h3\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric (Millions USD)\u003c\/th\u003e\n\u003cth\u003eFY 2024 Year-End (Dec 31, 2024)\u003c\/th\u003e\n\u003cth\u003eQ3 2024 (Sep 30, 2024)\u003c\/th\u003e\n\u003cth\u003eFY 2023 Year-End (Dec 31, 2023)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e491.15\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e422.0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e389.51\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUndrawn Revolving Credit Facility\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e125\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eEvolent Acquisition Financing Details\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eAcquisition of Evolent Health's ACO business for \u003cstrong\u003e$100 million\u003c\/strong\u003e in cash at closing.\u003c\/li\u003e\n\u003cli\u003eUp to an additional \u003cstrong\u003e$13 million\u003c\/strong\u003e contingent on final MSSP performance for 2025.\u003c\/li\u003e\n\u003cli\u003eTransaction financed with \u003cstrong\u003ecash on hand\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003ePro Forma Cash Position Context\u003c\/h3\u003e\n\u003cp\u003e\nThe cash balance as of September 30, 2025, was reported at \u003cstrong\u003e$441.4 million\u003c\/strong\u003e with no debt.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePro forma cash after the expected \u003cstrong\u003e$100 million\u003c\/strong\u003e payment to Evolent and inclusion of the 2024 MSSP receipt (\u003cstrong\u003e$68.5 million\u003c\/strong\u003e) was calculated at \u003cstrong\u003e$409.9 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrivia Health Group, Inc. (PRVA) - VRIO Analysis: 8. Strategic Acquisition and Integration Capability\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows for rapid expansion of VBC lives and geographic footprint. The Evolent ACO acquisition added over \u003cstrong\u003e120,000\u003c\/strong\u003e lives and a foothold in \u003cstrong\u003e11 new states\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many companies attempt M\u0026amp;A, but Privia demonstrated successful integration of the \u003cstrong\u003e$95 million\u003c\/strong\u003e IMS deal and the Evolent deal closing in the fourth quarter of \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. The ability to identify, negotiate, and integrate targets that fit the physician-friendly model is a learned skill. The company’s balance sheet at September 30, 2025, included cash and cash equivalents of \u003cstrong\u003e$441.4 million\u003c\/strong\u003e and \u003cstrong\u003eno debt\u003c\/strong\u003e, providing financial flexibility for such transactions.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The company has a clear M\u0026amp;A pipeline and successfully closed two significant deals in \u003cstrong\u003e2025\u003c\/strong\u003e, showing execution capability. The nine Privia ACOs achieved aggregate shared savings of \u003cstrong\u003e$234.1 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s an advantage only as long as they continue to find and successfully integrate accretive targets. Privia raised its full-year \u003cstrong\u003e2025\u003c\/strong\u003e revenue guidance to \u003cstrong\u003eUS$2.05–2.1 billion\u003c\/strong\u003e following these acquisitions and operational expansion.\u003c\/p\u003e\n\n\u003cp\u003eKey financial and operational metrics related to recent strategic acquisitions:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAcquisition Target\u003c\/th\u003e\n\u003cth\u003eTransaction Value (Upfront\/Closing)\u003c\/th\u003e\n\u003cth\u003eAttributed Lives Added\u003c\/th\u003e\n\u003cth\u003eNew States Added\u003c\/th\u003e\n\u003cth\u003eExpected EBITDA Impact\u003c\/th\u003e\n\u003cth\u003eImplementation\/Close Timing\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvolent Health ACO Business\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$100 million\u003c\/strong\u003e cash (up to \u003cstrong\u003e$13 million\u003c\/strong\u003e contingent)\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e120,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRoughly \u003cstrong\u003e$10 million\u003c\/strong\u003e run-rate adjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003eExpected Q4 \u003cstrong\u003e2025\u003c\/strong\u003e Close\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegrated Medical Services (IMS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$95 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e28,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eArizona\u003c\/strong\u003e (Entry)\u003c\/td\u003e\n\u003ctd\u003eEBITDA positive starting Q4 \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eImplementation Q4 \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eRecent operational scale and performance supporting M\u0026amp;A integration:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal attributed lives across all VBC arrangements post-Evolent deal: Approximately \u003cstrong\u003e1.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eImplemented Providers as of Q3 \u003cstrong\u003e2025\u003c\/strong\u003e: Grew \u003cstrong\u003e13.1%\u003c\/strong\u003e compared to Q3 \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePractice Collections for Q3 \u003cstrong\u003e2025\u003c\/strong\u003e: Increased \u003cstrong\u003e27.1%\u003c\/strong\u003e compared to Q3 \u003cstrong\u003e2024\u003c\/strong\u003e, reaching \u003cstrong\u003e$798.6 million\u003c\/strong\u003e in Q1 \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAdjusted EBITDA for Q3 \u003cstrong\u003e2025\u003c\/strong\u003e: Increased \u003cstrong\u003e61.6%\u003c\/strong\u003e compared to Q3 \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eEvolent deal is projected to contribute positively to Adjusted EBITDA in \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePrivia's current footprint prior to Evolent deal: \u003cstrong\u003e15 states plus Washington, D.C.\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrivia Health Group, Inc. (PRVA) - VRIO Analysis: 9. Data Analytics and Clinical workflow Integration (AI)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Specific tools, like the Navina AI assistant, directly improve documentation accuracy and close care gaps, which are critical inputs for VBC performance. Navina's recommendations are accepted at a rate of \u003cstrong\u003e74%\u003c\/strong\u003e across categories. The platform has been shown to reduce chart review time by \u003cstrong\u003e61%\u003c\/strong\u003e. Privia Health had over \u003cstrong\u003e800+\u003c\/strong\u003e physicians onboarded using Navina in the first year. One case study noted a \u003cstrong\u003e12%\u003c\/strong\u003e boost in quality metrics achieved with Navina. As of Q3 2025, Privia Health served \u003cstrong\u003e1.41 million\u003c\/strong\u003e Value-Based Care Attributed Lives.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While many use analytics, the broad rollout and proven impact of a specific AI tool on documentation burden is a newer, less common asset. As of the partnership announcement, over \u003cstrong\u003e4,700 users\u003c\/strong\u003e across \u003cstrong\u003e500 clinics\u003c\/strong\u003e were using Navina to enhance daily workflows.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Proprietary algorithms and the data sets used to train them are protected intellectual property.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The company highlights the success of this specific technology adoption, showing it’s embedded in operations, not just a pilot project. Privia Health achieved a Medicare Shared Savings Program (MSSP) 2023 Shared Saving of \u003cstrong\u003e$176.6 Million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Continuous, proprietary tech improvement creates a widening gap in efficiency over time.\u003c\/p\u003e\n\n\u003cp\u003eThe Evolent acquisition closing costs represent a significant cash outlay that must be managed within the 13-week cash flow projection. The total expected cash component for the acquisition is \u003cstrong\u003e$100 million\u003c\/strong\u003e at closing, with up to an additional \u003cstrong\u003e$13 million\u003c\/strong\u003e contingent on 2025 MSSP performance. The transaction is expected to add roughly \u003cstrong\u003e$10 million\u003c\/strong\u003e in adjusted run-rate EBITDA in 2026.\u003c\/p\u003e\n\n\u003cp\u003eThe following table outlines key operational and the known acquisition-related cash component relevant to near-term financial planning, as a component of the required 13-week cash flow projection structure:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\/Component\u003c\/th\u003e\n\u003cth\u003eValue (Latest Reported)\u003c\/th\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue-Based Care Attributed Lives (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.41 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLives\u003c\/td\u003e\n\u003ctd\u003ePre-Evolent acquisition close\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImplemented Providers (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5,250\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eProviders\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform Contribution (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$70.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents (Q3 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$422.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003eBalance sheet figure, no debt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvolent Acquisition Cash Closing Cost\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$100 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003eUpfront cash component of acquisition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvolent Acquisition Contingent Payment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003eSubject to 2025 MSSP performance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe integration of AI and data analytics supports the core business metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eImplemented Providers increased by \u003cstrong\u003e13.1%\u003c\/strong\u003e year-over-year for Q3 2024, reaching \u003cstrong\u003e4,642\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eValue-Based Care Attributed Lives grew by \u003cstrong\u003e14.0%\u003c\/strong\u003e year-over-year for Q3 2024, reaching \u003cstrong\u003e1,247,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFor the latest reported quarter (Q3 2025), Practice Collections were \u003cstrong\u003e$940.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFor the latest reported quarter (Q3 2025), Care Margin was \u003cstrong\u003e$125.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516235473045,"sku":"prva-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/prva-vrio-analysis.png?v=1740207645","url":"https:\/\/dcf-model.com\/fr\/products\/prva-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}